Identification of immune molecular markers for ischemic stroke based on genomic data

ZHANG Wenjing; XU Yaqi; HUANG Yiming; WANG Fenglin; WANG Aimin; WANG Qinghua; SHI Fuyan

doi:10.16462/j.cnki.zhjbkz.2024.06.008

Volume 28 Issue 6

Jun. 2024

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2024 > 28(6): 664-671

ZHANG Wenjing, XU Yaqi, HUANG Yiming, WANG Fenglin, WANG Aimin, WANG Qinghua, SHI Fuyan. Identification of immune molecular markers for ischemic stroke based on genomic data[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(6): 664-671. doi: 10.16462/j.cnki.zhjbkz.2024.06.008

Citation:

ZHANG Wenjing, XU Yaqi, HUANG Yiming, WANG Fenglin, WANG Aimin, WANG Qinghua, SHI Fuyan. Identification of immune molecular markers for ischemic stroke based on genomic data[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(6): 664-671. doi: 10.16462/j.cnki.zhjbkz.2024.06.008

Citation:

ZHANG Wenjing, XU Yaqi, HUANG Yiming, WANG Fenglin, WANG Aimin, WANG Qinghua, SHI Fuyan. Identification of immune molecular markers for ischemic stroke based on genomic data[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2024, 28(6): 664-671. doi: 10.16462/j.cnki.zhjbkz.2024.06.008

PDF( 8744 KB)

Identification of immune molecular markers for ischemic stroke based on genomic data

doi: 10.16462/j.cnki.zhjbkz.2024.06.008

Department of Public Health, Weifang Medical University, Weifang 261053, China

Funds:

National Natural Science Foundation of China 81803337

National Natural Science Foundation of China 81872719

National Natural Science Foundation of China 82003560

National Bureau of Statistics 2018LY79

Natural Science Foundation Project of Shandong Province ZR2019MH034

Natural Science Foundation Project of Shandong Province ZR2020MH340

Natural Science Foundation Project of Shandong Province ZR2023MH313

More Information

Corresponding author: WANG Qinghua, E-mail: wangqinghua@wfmc.edu.cn; SHI Fuyan, E-mail: shifuyan@126.com
Received Date: 2023-09-13
Rev Recd Date: 2024-01-06

Available Online: 2024-07-13

Publish Date: 2024-06-10

Abstract

Abstract

Objective To explore the immune-related molecular markers for ischemic stroke based on genomic data, and to provide theoretical basis for the prevention and clinical treatment of ischemic stroke. Methods GSE16561 and GSE58294 from the gene expression omnibus (GEO) database were used for the analysis and exploration of molecular markers immune-related to ischemic stroke. Based on the immunology database and analysis portal (ImmPort) database, immune-related genes were obtained and their differential expression in ischemic stroke group and normal controls group were also analyzed to identify differentially expressed immune genes (DEIGs). Immune-related hub genes were identified by protein-protein interaction (PPI). Pathway analysis of DEIGs was performed to find the possible molecular signaling pathways of ischemic stroke. Finally, the infiltration abundance of 22 immune cells was evaluated based on the CIBERSORT algorithm, and the difference between ischemic stroke group and normal control group was subsequently calculated to determine ischemic stroke-related immune cells. Results Differential analysis results showed that 37 DEIGs had statistically significant differences between two groups (all P < 0.05), including 31 up-regulated genes and 6 down-regulated genes in ischemic stroke samples. Pathway analysis results showed that the identified DEIGs were mainly enriched in immune-related molecular pathways. PPI analysis results showed that TLR4, TLR2, MMP-9, CCR7, STAT3, TNFSF13B, S100A12, CD19, CAMP and SLC11A1 were key hub immune genes closely related to ischemic stroke. Based on CIBERSORT results, we found that immune response cells were less enriched in ischemic stroke samples (all P < 0.05). However, the levels of immunosuppressive cells were higher (all P < 0.05). Conclusions Based on transcriptome expression data, this study identifies immune genes, immune signaling pathways and immune cells associated with ischemic stroke. This study reveals the immune molecular markers associated with ischemic stroke at three molecular levels, which is of great significance for the effective prevention and control of ischemic stroke and the formulation of targeted treatment strategies.
- Ischemic stroke,
- Immune genes,
- Signaling pathways,
- Immune cells,
- Molecular markers,
- Omics data

FullText(HTML)

References(26)

References

[1]	Collaborators G2S. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the global burden of disease study 2016 [J]. Lancet Neurol, 2019, 18(5): 439-458. DOI: 10.1016/S1474-4422(19)30034-1.
[2]	Harston GWJ, Rane N, Shaya G, et al. Imaging biomarkers in acute ischemic stroke trials: a systematic review [J]. AJNR Am J Neuroradiol, 2015, 36(5): 839-843. DOI: 10.3174/ajnr.A4208.
[3]	Zameer S, Siddiqui AS, Riaz R. Multimodality imaging in acute ischemic stroke [J]. Curr Med Imag Former Curr Med Imag Rev, 2021, 17(5): 567-577. DOI: 10.2174/1573405616666201130094948.
[4]	Shi KB, Zou M, Jia DM, et al. tPA mobilizes immune cells that exacerbate hemorrhagic transformation in stroke [J]. Circ Res, 2021, 128(1): 62-75. DOI: 10.1161/CIRCRESAHA.120.317596.
[5]	Iadecola C, Buckwalter MS, Anrather J. Immune responses to stroke: mechanisms, modulation, and therapeutic potential [J]. J Clin Invest, 2020, 130(6): 2777-2788. DOI: 10.1172/JCI135530.
[6]	Xu SB, Lu JN, Shao AW, et al. Glial cells: role of the immune response in ischemic stroke [J]. Front Immunol, 2020, 11: 294. DOI: 10.3389/fimmu.2020.00294.
[7]	Nikolic D, Jankovic M, Petrovic B, et al. Genetic aspects of inflammation and immune response in stroke [J]. Int J Mol Sci, 2020, 21(19): 7409. DOI: 10.3390/ijms21197409.
[8]	Wu F, Liu ZC, Zhou LH, et al. Systemic immune responses after ischemic stroke: from the center to the periphery [J]. Front Immunol, 2022, 13: 911661. DOI: 10.3389/fimmu.2022.911661.
[9]	O'Connell GC, Petrone AB, Treadway MB, et al. Machine-learning approach identifies a pattern of gene expression in peripheral blood that can accurately detect ischemic stroke [J]. NPJ Genom Med, 2016, 1: 16038. DOI: 10.1038/npjgenmed.2016.38.
[10]	Yang XT, Wang PY, Yan SQ, et al. Study on potential differentially expressed genes in stroke by bioinformatics analysis [J]. Neurol Sci, 2022, 43(2): 1155-1166. DOI: 10.1007/s10072-021-05470-1.
[11]	Stamova B, Jickling GC, Ander BP, et al. Gene expression in peripheral immune cells following cardioembolic stroke is sexually dimorphic [J]. PLoS One, 2014, 9(7): e102550. DOI: 10.1371/journal.pone.0102550.
[12]	Bhattacharya S, Andorf S, Gomes L, et al. ImmPort: disseminating data to the public for the future of immunology [J]. Immunol Res, 2014, 58(2-3): 234-239. DOI: 10.1007/s12026-014-8516-1.
[13]	Ritchie ME, Phipson B, Wu D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies [J]. Nucleic Acids Res, 2015, 43(7): e47. DOI: 10.1093/nar/gkv007.
[14]	Chen L, Zhang YH, Wang SP, et al. Prediction and analysis of essential genes using the enrichments of gene ontology and KEGG pathways [J]. PLoS One, 2017, 12(9): e0184129. DOI: 10.1371/journal.pone.0184129.
[15]	Chin CH, Chen SH, Wu HH, et al. CytoHubba: identifying hub objects and sub-networks from complex interactome [J]. BMC Syst Biol, 2014, 8 (Suppl 4): S11. DOI: 10.1186/1752-0509-8-S4-S11.
[16]	Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles [J]. Nat Methods, 2015, 12(5): 453-457. DOI: 10.1038/nmeth.3337.
[17]	Lorne E, Dupont H, Abraham E. Toll-like receptors 2 and 4: initiators of non-septic inflammation in critical care medicine? [J]. Intensive Care Med, 2010, 36(11): 1826-1835. DOI: 10.1007/s00134-010-1983-5.
[18]	Lissauer ME, Johnson SB, Bochicchio GV, et al. Differential expression of toll-like receptor genes: sepsis compared with sterile inflammation 1 day before sepsis diagnosis [J]. Shock, 2009, 31(3): 238-244. DOI: 10.1097/SHK.0b013e3181834991.
[19]	Tajalli-Nezhad S, Karimian M, Beyer C, et al. The regulatory role of Toll-like receptors after ischemic stroke: neurosteroids as TLR modulators with the focus on TLR2/4 [J]. Cell Mol Life Sci, 2019, 76(3): 523-537. DOI: 10.1007/s00018-018-2953-2.
[20]	Zhong CK, Yang JY, Xu T, et al. Serum matrix metalloproteinase-9 levels and prognosis of acute ischemic stroke [J]. Neurology, 2017, 22;89(8): 805-812. DOI: 10.1212/WNL.0000000000004257.
[21]	McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms [J]. J Neurosci, 2007, 27(16): 4403-4412. DOI: 10.1523/JNEUROSCI.5376-06.2007.
[22]	Kuol N, Stojanovska L, Nurgali K, et al. PD-1/PD-L1 in disease [J]. Immunotherapy, 2018, 10(2): 149-160. DOI: 10.2217/imt-2017-0120.
[23]	Gelderblom M, Weymar A, Bernreuther C, et al. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke [J]. Blood, 2012, 120(18): 3793-3802. DOI: 10.1182/blood-2012-02-412726.
[24]	Shichita T, Sugiyama Y, Ooboshi H, et al. Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury [J]. Nat Med, 2009, 15(8): 946-950. DOI: 10.1038/nm.1999.
[25]	Cai W, Liu SX, Hu MY, et al. Functional dynamics of neutrophils after ischemic stroke [J]. Transl Stroke Res, 2020, 11(1): 108-121. DOI: 10.1007/s12975-019-00694-y.
[26]	Wu ZQ, Lei K, Li HZ, et al. Transcriptome-based network analysis related to M2-like tumor-associated macrophage infiltration identified VARS1 as a potential target for improving melanoma immunotherapy efficacy [J]. J Transl Med, 2022, 20(1): 489. DOI: 10.1186/s12967-022-03686-z.